OTCM
HAWPF
Market cap2.24bUSD
, Last price
Name
Haw Par Corporation Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business activities are structured into three main segments: Healthcare, Investments, and Others. Its Healthcare segment primarily produces and distributes topical pain relief solutions, prominently featuring the Tiger Balm and Kwan Loong brands. The Investments segment focuses on acquiring publicly traded securities. Additionally, Haw Par owns and leases out a diverse portfolio of investment properties, comprising 45,324 square meters of commercial and industrial real estate across Singapore and Malaysia. The corporation also offers family and tourist-oriented leisure experiences, notably through oceanariums. Furthermore, it provides leasing services for land, buildings, and office spaces, in addition to offering management support.
Key people
Non-Executive Non-Independent Chairman of the Board · since 2024
Say Suan Chow
Chief Financial Officer · since 2022
Brian Loo
Group General Manager · since 2021
Wah Tong Ng
General Manager - Manufacturing of Healthcare · since 2024
President, Chief Executive Officer, Executive and Non-Independent Director · since 2003
Cindy Ow
Human Resource Director · since 2023
Jasmin Hong
General Manager - Marketing of Haw Par Healthcare Limited · since 2014
Chua Keeth
General Manager - Marketing of Haw Par Healthcare Limited · since 2020
Mui Lick Kow
Head - Quality & Regulatory Affairs of Healthcare · since 2022
Lily Su
Group Internal Audit Manager · since 2021
Sung Tze Whang
General Manager - Underwater World Pattaya Ltd · since 2011
Kun Lon Chiew
Group Finance Manager and Company Secretary · since 2022
Choon Soo Chew
Non-Executive Independent Director · since 2019
Huey Jee Lee
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2021
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||